A panel of human mAbs against JEV, including JEV-69, was generated from donors immunized with a GIII vaccine strain (JEV-SA14-14-2).
Alternative Names:
JEV
Reactivity Species : Japanese Encephalitis-Virus Expression Host : HEK-293 Endotoxin Level : 1.0 EU/mg as determined by the LAL method Specificity : Clone JEV-69 activity is directed against DIII-LR of the E protein. JEV-69 has no cross-reactivity to West Nile Virus or Zika Virus E proteins. Background : Japanese Encephalitis Virus (JEV) is a mosquito-borne, enveloped positive-stranded RNA virus in the Flavivirus genus endemic to Asia and parts of the western Pacific1. Symptomatic JEV infection is most common in children in areas of endemicity or travelers to those regions. Severe symptoms occur in ~1% of cases, with a case-fatality ratio of 2030%. Survivors often have neurologic, cognitive, or psychiatric sequelae issues. Five JEV genotypes have been identified, and existing vaccines are derived from historically predominant GIII strains2.
Clonality:
Monoclonal
Clone Designation:
[JEV-69]
Purity:
>=95% monomer by analytical SEC
* VAT and and shipping costs not included. Errors and price changes excepted
